Arrhythmic Effects of Hight Dose Caffeine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02045992|
Recruitment Status : Unknown
Verified September 2014 by Luis Eduardo Paim Rohde, Hospital de Clinicas de Porto Alegre.
Recruitment status was: Recruiting
First Posted : January 27, 2014
Last Update Posted : September 25, 2014
Heart failure patients represent a group of individuals at higher risk for cardiac arrhythmias. There is a perception that caffeine consumption may represent an increase in this risk. Although the medical staff and health professionals suggest a reduction in the intake of this substance to patients considered at risk, there is no scientific proof for this recommendation.
Some animal studies suggest a possible association between arrhythmias and caffeine use with higher doses, but this finding did not appear in human studies. In particular, little is known about the association between caffeine consumption and arrhythmias in patients with heart failure, especially at higher doses of consumption.
More specific and safe guidelines on caffeine consumption are needed.
|Condition or disease||Intervention/treatment||Phase|
|Arrhythmia||Dietary Supplement: caffeine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||112 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of High-dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure - a Randomized Clinical Trial|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||December 2015|
Dietary Supplement: caffeine
Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
Placebo Comparator: Placebo
- Arrhythmias [ Time Frame: 6 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02045992
|Contact: Priccila Zuchinali||5551 firstname.lastname@example.org|
|Hospital de Clínicas de Porto Alegre||Recruiting|
|Porto Alegre, Rio Grande do Sul, Brazil|
|Sub-Investigator: Priccila Zuchinali|